Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-7SHRNA for AIDS-related Lymphoma
NCT05922384Recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jul 2023
- Primary completion
- Sep 2025
- Modality
- Gene Editing, Viral-delivered RNAi, Gene Addition/Replacement
- Countries
- 1
01
Overview
Open-label, single-arm trial of KL-7SHRNA in human immunodeficiency virus infection (HIV) and lymphoma, sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoints: Overall Survival at 2 years and Engraftment time of 7shRNA modified CD34+ stem cells at 28 days. Started Jul 2023; status: recruiting.
02
Drugs
KL-7SHRNA
03
Conditions
human immunodeficiency virus infection (HIV)lymphoma
Beyond the preview
Go deeper on NCT05922384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05922384.